The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health And Inovio Pharmaceuticals
Zacks Investment Research | Mar 10, 2020 09:18PM ET
For Immediate Release
Chicago, IL – March 11, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Co-Diagnostics, Inc. (NASDAQ:CODX) , GenMark Diagnostics, Inc. (NASDAQ:GNMK) , OPKO Health Inc. (NASDAQ:OPK) and Inovio Pharmaceuticals Inc (NASDAQ:INO) .
Here are highlights from Tuesday’s Analyst Blog:
4 Stocks to Gain the Most from the Coronavirus Outbreak
The deadly coronavirus has claimed too many lives and experts believe it could cost the global economy in trillions. With no immediate respite in sight, the severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short, is likely to keep markets edgy for a while now.
However, several stocks are immune to the virus’ impact and, in fact, are expected to keep gaining.
Will the Epidemic Take the Shape of a Pandemic?
Considering the rapid spread across the globe, the virus eruption is now on the verge of being classified as a pandemic, said the World Health Organization.
Per compiled data of Johns Hopkins University, since the virus was first detected in China late last year, the total number of infected people across the world has increased to 113,584, as of Mar 9. Outside mainland China, the total number of cases surged from 10,000 a week ago to 30,665, the compiled data suggests. Notably, the count in the United States jumped to 605, including at least 25 deaths.
Stocks in the Watchlist
In the wake of the present scenario, one can choose to keep an eye on companies that are engaged in the prevention, diagnosis and treatment of the disease. Such stocks will not only protect investors from downside risks but are likely to continue gaining since there seems to be no immediate respite.
We are presenting one stock with a Zacks Rank #2 (Buy) and three with a Zacks Rank 3 (Hold) that are well positioned to gain. You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.